Lu-PSMA therapy: a breakthrough in prostate cancer treatment.

What Lu-PSMA actually is

Lu-PSMA therapy is a radioligand: a small molecule that finds prostate cancer cells anywhere in the body, locks onto them, and delivers a dose of radiation to each cell it touches.

The "PSMA" part is prostate-specific membrane antigen — a protein that sits on the surface of prostate cancer cells in much higher concentrations than on most other tissues. The "Lu" part is lutetium-177, a radioactive isotope that emits beta particles. The compound that ties them together is called PSMA-617 (sometimes vipivotide tetraxetan), a small molecule with a PSMA-binding "head" and a chelator "tail" that holds the radioactive lutetium.

When Lu-177 PSMA-617 is infused intravenously, it circulates briefly, then binds to PSMA on the surface of prostate cancer cells. The cell internalises the complex. Over the next several days, the lutetium-177 decays, emitting beta particles that travel an average of about 1 mm and deposit their energy locally. Cells with the most PSMA receive the most radiation. Cells without PSMA receive almost none. The salivary glands and kidneys, which express modest amounts of PSMA, receive some unintended dose — which is why xerostomia and renal effects appear in the side-effect profile.

This is the conceptual difference from chemotherapy, which works by interfering with cell division everywhere. Lu-PSMA's selectivity is why fatigue and dry mouth replace nausea and neutropenia at the top of the side-effect list.

What VISION actually showed

The pivotal evidence for Lu-PSMA in prostate cancer comes from the VISION trial, a randomised phase III study of 831 men with metastatic castration-resistant prostate cancer (mCRPC) who had already progressed through at least one androgen receptor pathway inhibitor (such as enzalutamide or abiraterone) and at least one taxane chemotherapy.^[1]

The headline numbers from the trial:

• Median radiographic progression-free survival: 8.7 months in the Lu-PSMA arm versus 3.4 months in standard care alone. The disease was held in check more than twice as long with the addition of Lu-PSMA.
• Median overall survival: 15.3 months versus 11.3 months. An extra 4 months of life at the median, in a patient population that had run out of other options.
• PSA response (any decline): 46 percent of treated patients. PSA decline of 50 percent or greater: 29 percent.
• Quality of life and pain scores: improved meaningfully in the Lu-PSMA arm.

What VISION did not show — and what is sometimes elided in promotional content — is that Lu-PSMA is not a cure, and it does not work for everyone. Roughly 30 percent of patients meeting eligibility criteria still progress within 6 months. The therapy buys time, often substantial time, often with better quality of life than the alternatives. It does not, in this disease state, eliminate the cancer.

The VISION outcomes led to the FDA approval of Pluvicto in March 2022 for post-chemotherapy mCRPC. In March 2025 the FDA expanded the indication to allow Lu-PSMA before chemotherapy in selected patients, on the basis of the PSMAfore trial data. Both indications are now in active use at specialist centres worldwide.^[2]

Who is eligible

The standard eligibility set is precise. Five conditions must be met:

The PSMA PET-CT is the single most important gatekeeper. It is not enough to have prostate cancer; the cancer must show up on the PSMA scan. Approximately 10 to 15 percent of men with mCRPC have insufficient PSMA expression to benefit. For these men, alternatives — typically Ac-225 PSMA therapy if some PSMA expression exists, or other systemic options — are discussed. The PSMA PET also serves as the dosimetry foundation for the actual treatment plan.

If you are considering Lu-PSMA and have not yet had a PSMA PET-CT, that is the first investigation. We frequently see patients who are offered Lu-PSMA based on a CT or bone scan alone — that is not adequate. A second-read service is available for those who already have a PSMA PET from an outside centre and want an expert review before treatment.

How a course is delivered

A standard Lu-PSMA course is between four and six cycles, given approximately every six weeks. Each cycle is a single intravenous infusion of about 7.4 GBq (200 mCi) of Lu-177 PSMA-617, taking about 20 to 30 minutes. The patient is then radiation-precaution monitored for a few hours and discharged the same day.

Between cycles, the team monitors:

• Blood counts — to ensure the marrow is recovering between doses
• Renal function — to confirm the kidneys are tolerating the cumulative dose
• PSA — to track biochemical response
• Imaging — typically a CT or PSMA PET after cycle 2 or 3 to assess radiographic response

If response is excellent and tolerance good, the full six cycles are delivered. If there is no biochemical or imaging response after two to three cycles, the team has an honest conversation about stopping. Continuing a therapy that is not working serves no one.

Side effects, honestly

The Lu-PSMA side-effect profile is, by oncology standards, mild. The honest list is below.

Common

• Fatigue — around 40 to 50 percent of patients. Typically peaks 7 to 10 days after each infusion and resolves by week three.
• Xerostomia (dry mouth) — around 40 percent. The salivary glands take some unintended PSMA-mediated radiation. Mostly mild; severe xerostomia is uncommon with Lu-PSMA (more common with Ac-225 PSMA — see our xerostomia guide).
• Nausea — 30 percent. Usually managed with standard antiemetics.
• Anaemia, thrombocytopenia, leukopenia — measurable in most patients, severe in roughly 10 percent. Recovery typically full between cycles.

Less common but worth knowing

• Renal effects — small declines in eGFR over a course; serious renal toxicity is uncommon with Lu-PSMA in typical dosing.
• Loss of taste — temporary, related to xerostomia, usually recovers.
• Constipation, dry eyes — minor, manageable.

Compared with the docetaxel and cabazitaxel chemotherapies that most Lu-PSMA candidates have already received, the side-effect burden is generally lower. Many patients describe feeling roughly normal between cycles, which is a stark contrast to the recovery cycle of taxane chemotherapy.

What response looks like

Response to Lu-PSMA is tracked through three windows:

• PSA. The earliest and most accessible signal. A PSA decline that begins to be visible after cycle 1 and consolidates by cycle 3 is the typical pattern of a responder. The 50 percent decline benchmark from VISION applies to roughly 29 percent of patients; smaller declines are also common and clinically meaningful.
• Imaging. A CT or follow-up PSMA PET after cycle 2 or 3 confirms radiographic response — shrinkage of soft-tissue disease, reduction in the number or intensity of bone lesions on PSMA scan, no new sites.
• Symptoms and quality of life. Pain reduction is one of the most patient-meaningful endpoints. In VISION, pain scores improved measurably in the treatment arm. Energy, appetite, and the experience of "feeling more like myself" tend to follow over the course of the cycles.

If none of these is moving by cycle 3, the team will discuss honest options. Lu-PSMA is not a therapy to push past the point of clear non-response. It is a therapy to use while it is working, then to move on from.

Cost: US vs India

Honest disclosure: cost is a defining factor in access to Lu-PSMA worldwide. The figures below are indicative ranges, not quotes. Final pricing is confirmed after the planning PSMA PET and clinical evaluation.

• United States — The publicly disclosed Pluvicto list price for a complete six-cycle course at major US oncology centres is approximately USD 240,000 (around USD 40,000 per cycle), before insurance adjustments. Many US patients have meaningful out-of-pocket exposure even with insurance.
• India — A complete course at FMRI is in the indicative range of INR 12 to 18 lakh, depending on the number of cycles required, dosimetry needs, and supportive care. This translates to roughly USD 14,000 to 22,000 for a complete course — approximately one-tenth of the US list price for the same active agent.

For international patients, the cost differential is substantial enough that medical travel for Lu-PSMA from the United States, the United Kingdom, the Middle East, and Southeast Asia is now common at FMRI. The therapy delivered in India uses locally produced Lu-177 PSMA-617 of equivalent specification to Pluvicto. The active radioligand is identical; the cost is different because of pharmaceutical pricing, not because of clinical compromise.

Where Lu-PSMA fits

The clean way to think about Lu-PSMA in the prostate cancer treatment landscape is as a tool used at a specific moment in the disease trajectory. The trajectory looks roughly like this:

• Localised disease — surgery (radical prostatectomy) or radiation therapy. Lu-PSMA has no role here.
• Biochemical recurrence after primary treatment — local salvage (radiation, surgery, or focal therapy depending on findings). Lu-PSMA still not indicated.
• Hormone-sensitive metastatic disease — androgen deprivation therapy plus an androgen receptor pathway inhibitor or chemotherapy. Lu-PSMA still not standard.
• Castration-resistant disease (mCRPC), pre-chemotherapy — under the expanded FDA label (Mar 2025), Lu-PSMA can now be considered before taxane chemotherapy in selected patients with high-PSMA-expressing disease.
• Castration-resistant disease, post-chemotherapy — the original VISION indication. Lu-PSMA is a standard option.
• Lu-PSMA progression — if disease progresses on Lu-PSMA, alpha-emitter Ac-225 PSMA therapy can sometimes recover response. See our Lu-177 vs Ac-225 comparison.

The right time to bring Lu-PSMA into the conversation is generally before the patient runs out of standard options — earlier than the traditional last-line position. The data has shifted forward over the past three years.